Abstract

Prognostic or predictive somatic genetic biomarkers influence therapeutic decisions in oncology. With the availability of next-generation sequencing (NGS) technologies, large numbers of somatic and germ line mutations can be analysed in parallel both, from formalin-fixed, paraffin-embedded tissue (FFPE) and fresh frozen tissue at high quality. In this study we evaluated the feasibility, turn-around time and diagnostic usefulness of highthroughput NGS analyses in the clinical setting and offered two different diagnostic sequencing panels to 52 selected patients.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.